Interview | Innovative drug lights up nerve repair

Article Summary.

The etiology and mechanism research of brain science is very complex, there are about 4,000 rare diseases, of which 1,700 are encephalopathies, for the prevention of major encephalopathies and [...]

The etiology and mechanism of brain science is very complex, there are about 4,000 kinds of rare diseases, of which 1,700 belong to the brain disease, for the prevention and treatment of major brain diseases is the focus of current research.2024 Showcase of scientific and technological innovations in the field of neuropsychiatryIt was held in Beijing on August 25, in which brain-computer interface, implantable neuromodulation technology, and innovative drugs for neuroprosthetics were awarded as 10 outstanding showcase projects. KSA Channel conducted interviews with the research teams of some of the project results to share the research progress related to innovative drugs for neural repair.

"Patients with acromegaly are in a clear state of mind, and it is a very painful process to watch themselves slowly walk to the end of their lives, while all the clinical drugs on the market now have no way to achieve the reversal of the state." Wang Yu, the chairwoman of Beijing Darwin Cell Biotechnology Co., Ltd, is very concerned about the current state of medical treatment of neurological diseases, and her team has developed the innovative biologic drug "Alitol" in the research and development of Class 1 after a long period of hard work, which has a goodNeurorestorative effects, and has passed IIT (investigator-initiated clinical studies) and will hopefully fill a number of gaps in clinical needs for neurological disorders.

Multi-target, multi-pathway innovation to give patients new hope

Yanbo Chen, director of the Darwin Center Laboratory, compared the process of repairing neurons in patients with neurological disorders to building construction, saying that the "building materials" used for neurons come from the patient's body, and that the inability to balance "construction" and "destruction" leads to "destruction" as a result. The inability to achieve a balance between "construction" and "destruction" leads to "destruction. The research team is trying to reverse this trend by making neurons more involved in the construction process."Construction"Neurological diseases are complex. Neurological diseases have complex pathogenic factors, and many past studies have tried to find a single target for drugs to work, but failed to achieve the goal. Yanbo Chen and his research team have built on the foundation of previous studies to innovate.Seeking ways for drugs to work in multiple targets and pathways. They are instem cell derivativeAlitol has found a breakthrough in the application of stem cells, which can not only avoid the risks in the application of stem cells itself, but also effectively control the cost. Relying on the stress-inducing technology of mesenchymal stem cells and inducing the screening of multifunctional proteins, Alito can reduce the effects of various stressors, relieve and release the pressure of neurons, so that they can better mobilize their own repair capacity to restore the function of the nervous system. Wang Yu has realized from the patients he has followed for a long time that the core issue lies in whether the drug can produce the following effectsReversing the trend of the disease. "The patient's legs or arms are moving again, and that manifestation, even a little bit, gives very great hope." Research into neurological disorders has been going on for hundreds of years, and any breakthrough is invaluable. "The introduction of Alitol could bring new solutions to the field of nerve repair, and it has been shown in clinical studies of tachyphylaxis IIT conducted at Tiantan Hospital and Yuquan Hospital of Tsinghua University.Effectively inhibit and, to some extent, reverseTrends in neurologic decline in patientsThe efficacy of theAchieved the first score recovery in the globally recognized gold standard for efficacy evaluation in the field of acromegaly, and is in compliance with the NIDA Breakthrough Therapy Recognition. Its clinical efficacy in the clinical management of stroke is also superior to that of existing drugs, theFilling a clinical gap in the subacute and recovery phasesThe

Opening up a broad clinical perspective with in-depth research

With the aging of the population, the incidence of neurological diseases is increasing, which has led to a significant increase in the number of patients and healthcare investment. "Alitol" is expected to address the pathogenesis of neurological disorders including Alzheimer's disease, Parkinson's disease, and childhood autism, and has the ability toPotential for Broad SpectrumMr. Wang hopes to verify whether the mechanism of action of Alito is directly related to the pathogenesis of the above diseases. Wang hopes to verify whether the mechanism of action of Alitol directly corresponds to the pathogenesis of the above diseases, and to expand the IIT clinical study to 10 diseases next year. Rare disease research seldom produces outstanding results, so Alitol can provide all the researchers withNew directions and research leads. "This could be a reminder to drug companies around the world to shorten their research time by many years." Wang Yu and Chen Yanbo are looking forward to "Alito" out of the laboratory, into the clinic as soon as possible, really bring the gospel to the patients. However, because it is an innovative drug, neither the peer experts and scholars nor the approval department have an in-depth understanding of the relevant aspects of the recruitment of patients and clinicians to withstand the huge risks, must rely on theSufficiently rich data from basic and clinical studiesOnly then will it be widely recognized. Relying on the green channel for approval of rare disease drugs by the State Drug Administration, Alito is expected to speed up the progress of filing and complete the listing and approval.

The whole industry chain joins hands to climb the peak of drug research and development

Wang Yu pointed out that Chinese clinicians need to balance the weight of their daily diagnosis and treatment work and clinical research work, and it is not easy for them to put in a lot of energy and time without delaying their immediate work. Early research institutes were often dedicated to in-depth research on a subtle aspect, and it was difficult to translate the results of research in the laboratory to serve the patient population. Chen Yanbo also believes that researching complex and highly prevalent neurological diseases is like climbing one mountain after another, and it is difficult to overcome them with the strength of a single company or research organization. In order to solve the clinical needs in the fastest way, it is necessary to combine the strengths of all parties to accelerate the realization of the research. Therefore.Whole Industry Chain Cooperationis a must for drug discovery and development.industrial agglomerationIt is also a necessary process to accelerate the marketing of new drugs. Wang Yu and Chen Yanbo concluded, "We hope that we can work hand in hand to bring together the contributions from various fields of industry, academia, research and economics, and twist our strengths into a rope to scale the heights together."